Peptide News Digest

AMA Opposes HHS Peptide Policy, Aravax Peanut Allergy Peptide Trial, Compounded GLP-1 Additives

The AMA urges HHS to drop its peptide policy as comments close, a peptide therapy aids peanut-allergic kids, and a JAMA study tracks compounded GLP-1 additives.

12 stories · Covering regulatory, industry, clinical-trials, research

Editor's Note

Public comments on HHS's plan to let pharmacies compound six unapproved peptides closed on November 13, days after the American Medical Association voted to ask for the policy's repeal. In Australia, regulators found no TB-500 in Synedica-branded products labeled with it. A University of Utah study points to a related blind spot for GLP-1 drugs: most compounded weight-loss prescriptions in Nebraska are now compounded GLP-1s, often mixed with vitamin B12 that has never been tested with them. The clinical news came from peptides built for the immune system. Aravax's monthly peptide therapy raised the amount of peanut that allergic children could eat, and a Duke vaccine trial in glioblastoma met its safety goals. Cost still shapes how people get these drugs. Koreans are planning trips to Japan for cheaper Mounjaro, private GLP-1 purchases in Italy rose 85.7% in a year, and North Dakota became one of 29 states to cap what patients pay for insulin.

AMA Asks HHS to Rescind Its Peptide Compounding Policy as Public Comments Close on November 13

At its Interim Meeting in Orlando, the American Medical Association adopted policy urging HHS and the FDA to "immediately rescind" directives that ease compounding of unapproved synthetic peptides, and to pursue enforcement against compounding pharmacies, telehealth platforms, and online sellers. AMA board member Ilse Levin said patients face "serious, preventable harm." HHS's comment period on its policy covering BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 closed at the end of November 13, with 115 comments posted on Regulations.gov by that day.

Australian Hepatitis Groups Urge Sterile Injecting as TGA Tests Find No TB-500 in Three Synedica Peptide Products

Hepatitis Australia and the Australasian Society for Infectious Diseases urged people injecting peptides to use new sterile equipment every time, citing Kirby Institute data showing that the share of needle-exchange visits tied to anabolic agents and hormones rose from 9% in 2022 to 14% in 2025, Medical Republic reported. Days earlier, TGA lab testing found no TB-500 in three Synedica products labeled with it, including the KLOW and BARBIE KLOW blends, and less retatrutide than stated in Synedica Retatrutide 10 mg.

Koreans Plan Day Trips to Japan for Cheaper Mounjaro After Seoul Eases Personal Import Rules

The Korea Herald reported that, after Korea began allowing up to a three-month supply of medicines bought legally abroad, one forum user estimated that a Fukuoka day trip with three months of 5 mg Mounjaro would cost about 700,000 won ($520), against more than 1 million won at home. Customs caught 5,030 unauthorized imports of drugs such as Mounjaro and Wegovy in the first eight months of 2026, more than four times the 1,189 cases in all of 2025.

NPR: North Dakota Joins 29 States Capping Insulin Costs at $25 a Month After Families Testified in Bismarck

NPR and KFF Health News reported that North Dakota's Republican-majority legislature passed a $25-a-month cap on what patients in state-regulated plans pay for insulin. Insurers and the state chamber of commerce opposed it, warning of higher premiums. Average yearly out-of-pocket insulin costs for privately insured patients fell from $470 in 2018 to $220 in 2025, but state caps do not reach most plans from larger employers, which are typically regulated by the federal government.

Italy's Private Purchases of GLP-1 Drugs Rose 85.7% in a Year as Endocrinologists Warn About Shared and Counterfeit Pens

Il Sole 24 Ore reported that, according to Italian drug regulator AIFA's OsMed 2025 report, private purchases of GLP-1 and dual GIP/GLP-1 drugs rose 85.7% in volume and 75.8% in spending compared with 2024. At their congress in Rome, members of the Association of Medical Endocrinologists warned about drugs passed to relatives and counterfeits sold online. They pointed to a 31-year-old woman in Padua who fell into a hypoglycemic coma in 2025 after injecting a fake incretin that contained insulin.

Circana: 37% of U.S. Households Have Had a GLP-1 User, and Candy Spending Rebounds Above Baseline by Year Two

Circana's GLP-1 Unlocked report found that 37% of surveyed U.S. households have had someone use a GLP-1 drug, up from 17% in 2024, and 30% have a current user. Restaurant spending in these households dipped in the first year of treatment, then returned to within 0.5 index points of its starting level in year two, while candy rose 5.7 points above baseline. Of households where someone had stopped, 48% said they were at least somewhat likely to restart within a year.

Aravax's Monthly Peptide Therapy PVX108 More Than Doubled the Peanut Dose Allergic Children Could Tolerate in Phase 2

In children aged 4 to 11, the maximum tolerated peanut dose after 12 months rose 2.4-fold on PVX108 50 nmol (23 children) versus 1.2-fold on placebo (24 children), Aravax said, and 39.4% versus 16.7% tolerated a cumulative 443 mg of peanut protein. The company reported no treatment-related allergic reactions or anaphylaxis. The monthly injection uses peptides designed to retrain T cells to tolerate peanut. Results from the 14-site U.S. and Australian trial are company-reported ahead of a November 14 presentation at the ACAAI meeting in Phoenix.

Duke's ETAPA Trial: Peptide Vaccine P30-EPS Met Its Safety Goals in 18 Adults With Hard-to-Treat Glioblastoma

In an abstract for the Society for Neuro-Oncology meeting, Duke researchers reported that 18 adults with newly diagnosed MGMT-unmethylated glioblastoma received up to seven doses of P30-EPS after radiation. The vaccine links cytomegalovirus pp65, survivin, and EphA2 peptides to a tetanus toxoid epitope, and was given with the immune stimulant Hiltonol. All treatment-related side effects were grade 2 or lower, 11 patients showed antigen-specific T-cell responses, and median progression-free and overall survival were 9.7 and 15.3 months in this single-arm study.

University of Utah Study in JAMA: Compounded GLP-1s Rose to 86% of Nebraska's Compounded Weight-Loss Prescriptions, Often With Vitamin B12

Using Nebraska's prescription monitoring database, Joey Mattingly's team found compounded GLP-1s went from zero in 2018 to 86% of all compounded weight-loss prescriptions in 2025, almost all paid in cash. Common additives included vitamin B12 analogs such as cyanocobalamin and levocarnitine, which are marketed to ease side effects but have not been tested for safety with GLP-1s, the university said. Mattingly urged doctors to ask patients directly about compounded use, since it rarely shows up in claims data.

Records of 7,965 Patients: Tirzepatide Users Lost More Lean Mass Than Semaglutide Users, but Only Because They Lost More Weight

An nference analysis in npj Exercise Medicine and Health drew on health records for 670,422 first-time users, 7,965 of whom had body-composition readings before and after treatment. Tirzepatide was linked to 2.1 percentage points more relative lean-mass loss at 12 months, but the gap disappeared after adjusting for total weight lost. Lean mass made up about 20% of the weight lost on either drug. More than 20% weight loss with over 5% lean-mass loss was more common on tirzepatide (10.3% vs. 6.7%).

Case Report: Wegovy Dose Increase May Have Triggered Two Positive Ignition Interlock Tests in a Sober Woman

A Minnesota consultant described a 45-year-old woman who failed two ignition interlock breath tests within days of raising her Wegovy dose from 1.0 mg to 1.7 mg, though she said she had been sober for years. The report in the Medico-Legal Journal proposes that eating less pushed her body to burn fat. That would raise acetone, which can convert to isopropanol, a substance fuel-cell breath sensors read as alcohol. The author says the mechanism should be considered in disputed interlock violations by GLP-1 users.

MOTS-EM2, a Fusion of MOTS-c and an Opioid Peptide, Kept 78% of Its Pain Relief After Eight Daily Doses in Mice

Researchers at Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine joined the mitochondrial peptide MOTS-c to endomorphin-2, a natural opioid peptide. In mouse models of acute, inflammatory, and nerve pain, the fusion relieved pain longer than endomorphin-2 alone and retained 78.09% of its effect after eight daily injections, versus 20% for endomorphin-2. It slowed gut transit less and did not impair movement, but still showed some addiction potential, the team wrote in the International Journal of Peptide Research and Therapeutics.